BALCHEM CORP
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.0B | $953.7M | $922.4M | $942.4M | $799.0M |
| Cost of revenue | $666.5M | $617.5M | $620.4M | $661.9M | $555.8M |
| Gross profit | $370.6M | $336.2M | $302.1M | $280.5M | $243.2M |
| Research and development | $18.5M | $16.8M | $15.0M | $12.2M | $13.5M |
| Operating expenses | $161.3M | $153.3M | $142.9M | $135.3M | $115.7M |
| Operating income | $209.3M | $182.9M | $159.2M | $145.2M | $127.5M |
| Pretax income | $199.0M | $166.5M | $137.3M | $133.7M | $125.2M |
| Income tax expense | $44.2M | $38.0M | $28.7M | $28.4M | $29.1M |
| Net income | $154.8M | $128.5M | $108.5M | $105.4M | $96.1M |
| Balance Sheet | |||||
| Cash and equivalents | $74.6M | $49.5M | $64.4M | $66.6M | $103.2M |
| Current assets | $365.6M | $313.8M | $314.2M | $335.8M | $322.2M |
| Total assets | $1.7B | $1.6B | $1.6B | $1.6B | $1.2B |
| Current liabilities | $176.4M | $157.7M | $148.5M | $140.0M | $143.8M |
| Total liabilities | $428.8M | $425.5M | $543.2M | $686.2M | $322.3M |
| Stockholders' equity | $1.3B | $1.1B | $1.1B | $938.3M | $877.0M |
| Cash Flow Statement | |||||
| Cash from operations | $216.6M | $182.0M | $183.8M | $138.5M | $160.5M |
| Depreciation and amortization | $45.7M | $48.0M | $54.9M | $51.8M | $48.9M |
| Stock-based compensation | $18.1M | $16.7M | $16.1M | $13.2M | $10.8M |
| Capital expenditure | — | — | — | $49.1M | $36.1M |
| Free cash flow | — | — | — | $89.5M | $124.4M |
| Dividends paid | $28.3M | $25.6M | $22.9M | $20.7M | $18.7M |
| Share repurchases | $107.6M | $5.7M | $4.5M | $35.4M | $35.2M |
| Impairments | $0 | $521,000 | $7.8M | $23,000 | $1.7M |
Shares outstanding 32.1M · Free float 98.4%
Annual filing data through FY ended December 31, 2025; float as of July 8, 2026.